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Letters

The Clinical Research Forum and
Association of American Physicians
disagree with criticism of the NIH Roadmap
As representatives of 50 leading academic medical centers focusing on clinical research and many of academic medicine’s scientific leaders, the Clinical
Research Forum and Association of American Physicians disagree with the
JCI’s recent editorials on the NIH Roadmap, Elias Zerhouni’s leadership,
and the future directions of biomedical research.
Two critical features about NIH’s clinical research merit emphasis are that it is (a)
hypothesis-driven and (b) crucial to the public. Without the translation from theory to
practice, public support for science rapidly
dissipates. In contrast, industry must focus
on profit-generating opportunities, the
fundamental covenant with their investors.
Industry is not burdened with sustaining the
issues specific to academic science. Rather,
such matters are largely left to the NIH and
academic medical centers to address. Investigator recruitment, training, and retention;
maintenance of clinical research careers;
and funding of the facilitating and regulatory infrastructures for the national clinical
research enterprise are simply not on industry’s agenda. Partnerships among academic
medical centers, the NIH, and others largely
support our nation’s translational research
engines. Other expensive elements of clinical research include the regulatory and
safety requirements of institutional review
boards, the Office of Human Research Protection, and the FDA. The partnerships with
academic centers represent further complications not encountered in basic laboratory
science nor in industrial funding arrangements. A healthy clinical research enterprise
requires the cooperation of many to fulfill
the public’s expectations that their investments in basic medical research via the NIH
are worthwhile. Only synergy among these
various spheres will bring the public what it
desires in future health care.
The JCI editorials (1, 2) argued that
the Roadmap and reengineering clinical

research are untimely investments. Again,
we disagree. The NIH director’s concern
for the integrity of the clinical research
enterprise arises directly from numerous
well-documented Institute of Medicine
studies over 2 decades (3–5). Their most
recent Clinical Research Roundtable clearly
reidentified many of the same problems
beleaguering clinical research and outlined
potential solutions (5, 6). The NIH director
appropriately incorporated many of these
issues into the NIH Roadmap.
We believe Dr. Zerhouni is vitally concerned with helping Congress and the
public to understand the return in public
health they get from their investment in
medical research. He is visionary and correctly emphasizes that medical science is
on the brink of transforming medicine.
He is unafraid to make necessary changes
and understands the necessity of innovative risk taking. He is a prudent steward
of public resources, advancing the clinical
research agenda in an appropriate manner
relative to total NIH resources.
We do not expect the current funding crisis to abate soon. Therefore, we suggest that
our colleagues consider carefully how to
conduct this dialogue. These discussions are
not restricted to the science community but
must involve the government, the media,
patients, and the public. We must redouble
our collective efforts to assist the NIH director in documenting the return on investment from publicly supported research. We
should not pit basic science against clinical
science. Rather, we must advocate collectively and effectively for a balanced investment
that serves the relevant needs of both and
continue our advocacy for adequate support
for the entire medical research enterprise.
Our nation deserves nothing less than our
collective and collegial efforts.
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Following an unprecedented doubling, all
agree that the flattening of the NIH budget
in the last 3 years has dampened momentum in our nation’s medical research. The
doubling of our nation’s investment in
biomedical research occurred as deficits
became surpluses, support became bipartisan, and the nation’s imagination was
fueled by remarkable achievements such as
the Human Genome Project and treatments
for HIV. Flat budgets have now emerged as
taxes decrease, war expenditures escalate,
entitlement programs increase, and ballooning annual budget deficits reemerge.
Predictably, bipartisan support for science
has disappeared. The negative consequences for medicine will be profound.
Thus, advocating for parochial interests
at this juncture is unseemly and ineffective.
Basic and clinical researchers must hang
together or, as Benjamin Franklin said, they
will assuredly hang separately. Only broad,
coordinated action by scientists and the public will reverse this deplorable situation. Angst
in recent editorials (1, 2) has focused on the
NIH Roadmap (currently using only 1% of
the NIH budget) and its goal to reengineer
the national clinical research enterprise. The
view expressed was that the NIH should rely
more heavily on pharmaceutical companies
to fund large clinical trials in order to reallocate more funds to R01 grants, which are
traditionally more basic science in nature. We
strongly disagree. NIH’s mission demands a
balanced commitment to basic and clinical
research, harnessed together in the interest
of improving the nation’s health.
Clinical Research Forum Steering Committee
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